JAZZ vs LGN · P/E 1988, rev $2.28B vs rev $2.55B
Jazz Pharmaceuticals PLC (JAZZ) versus Legence Corp. Class A Common stock (LGN) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Legence Corp. Class A Common stock (LGN) is a engineering & construction company listed on NASDAQ.
Latest reported JAZZ revenue for 2026-06-30 was $2.28B. Net income was $485.9M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Latest reported LGN revenue for 2025-12-31 was $2.55B. Net income was -$59.8M. Revenue was up 21.5% from 2024-12-31 to 2025-12-31. LGN currently screens at market cap $14.66B.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. LGN currently screens at market cap $14.66B.
Not investment advice. Open the JAZZ and LGN stock pages for the full models.
Not investment advice.